News

New US contracts cool conflict
Enlarge image

BusinessDenmark

New US contracts cool conflict

15.11.2012 - Despite an ongoing dispute, the US government has signed two new contracts with Danish vaccine developer Bavarian Nordic.

The Danish drugmaker announced the closing of two new contracts with the U.S. Department of Homeland Security (DHS) and the National Institutes of Health (NIH). The contracts were valued at up to US$18.9m for the development of recombinant Modified Vaccinia virus Ankara (MVA) vaccines.

The NIH contract, valued at up to US$17.9m, supports the advanced development of an MVA-based human vaccine against the viral haemorrhagic fever Marburg. The DHS contract, valued at nearly US$1m, supports the development of an MVA-based animal vaccine against Foot-and-mouth disease. "These new contracts demonstrate the versatility of our MVA platform for infectious disease vaccines and cancer immunotherapeutics," said Anders Hedegaard, President and CEO of Bavarian Nordic A/S.

Bavarian Nordic is currently in an argument with the US government. Denmark's biggest drugmaker accuses its customer not to fulfil the conditions of a 2007 contract worth US$500m. The government had promised to order 20 million doses of a smallpox vaccine that has less side effects than common ones. As Bloomberg noted, the biotech company had said in August that it would have to shed hundreds of jobs and shut down a plant if the U.S. government didn't order more of the vaccine until January.

© eurobiotechnews.eu/pd

http://www.european-biotechnology-news.com/news/news/2012-04/new-us-contracts-cool-conflict.html

BusinessBelgiumSpain

31.07.2015 Spanish business developer Genetrix has sold its clinical stage cell therapy development subsidiary Coretherapix to Belgian TiGenix in a deal worth up to €267m.

BusinessUKSwitzerland

29.07.2015 Newly founded Mereo BioPharma has acquired three mid-stage clinical assets from Novartis. In turn, the Swiss pharma concern will hold a stake in the UK company. Other investors are also on board.

M&AIreland

28.07.2015 Irish Allergan is bolstering its product pipeline with a takeover of CNS specialist Naurex. At the same time, the company is divesting its global generics business to Teva.

Public marketGermanyFranceBelgiumFinlandDenmarkUK

24.07.2015 Biotech companies across Europe continue to raise cash on the public markets, generating €3bn in total financing proceedings in the first half of 2015. Compared to 2014, this is almost twice as much.

FinanceFrance

23.07.2015 US money keeps flowing into Europe's biotechs. As the race for the peanut allergy market heats up, NASDAQ listed French biotech DBV has announced the successful closing of US$281m (€256m) share offering for its allergy products.

BioplasticsFrance

21.07.2015 French biotech Deinove has launched a R&D programme to produce the versatile chemical intermediate muconic acid by using a designer variant of the Deinococcus bacteria.

BusinessFrance

16.07.2015 Sanofi has announced plans to restructure its business in five standalone global business units starting in January 2016. The goal is to promote growth and help the company launch a catalogue of new drugs over the next five years.

R&DUK

15.07.2015 GlaxoSmithKline (GSK) has become the first drugmaker to join the Francis Crick Institute. It is a consortium made up of six scientific and academic institutes to conduct research and drug development in the UK. The new institute is set to become a world-leading centre of biomedical research and innovation.

FundingUK

13.07.2015 UK drug developer ReNeuron has pulled in £68.4m (€96m) for its cell therapy pipeline for stroke and blindness treatments. Biotech guru Neil Woodford increases his fund’s stake in ReNeuron.

BusinessSweden

10.07.2015 Karolinska Development has slashed the reported value of its portfolio by almost half by revising its valuation model for early stage companies and divesting its shares in pain med maker Pharmanest.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • SERODUS (N)2.60 NOK4.00%
  • SUMMIT (UK)4.03 GBP3.87%
  • FLAMEL TECHNOLOGIES (F)23.88 USD3.83%

FLOP

  • BASILEA (CH)103.50 CHF-13.10%
  • ZELTIA (E)3.69 EUR-8.44%
  • DIAMYD MEDICAL -B- (S)9.20 SEK-6.60%

TOP

  • IXICO (UK)34.00 GBP44.7%
  • DBV TECHNOLOGIES (F)78.26 EUR40.4%
  • ZEALAND PHARMA (DK)149.00 DKK31.9%

FLOP

  • BIOTEST (D)25.40 EUR-64.2%
  • BIOTECH PHARMACON (N)9.74 NOK-43.0%
  • TRANSGENE (F)2.81 EUR-25.1%

TOP

  • ADOCIA (F)88.47 EUR590.6%
  • FORMYCON (D)28.89 EUR330.6%
  • DBV TECHNOLOGIES (F)78.26 EUR312.3%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-88.9%
  • NEUROVIVE PHARMACEUTICAL AB (S)22.00 SEK-70.8%
  • NEOVACS (F)1.02 EUR-68.6%

No liability assumed, Date: 31.07.2015